Ludwig Enterprises, Inc. aksje
LUDG
StengtLudwig Enterprises, Inc.
Market Cap
$5,015,007
Om Ludwig Enterprises, Inc. aksje
Ludwig Enterprises, Inc. operates as a genomic technology focused on developing testing approaches for inflammation-related chronic diseases, including cancers in the United States. The company integrates mRNA inflammatory biomarkers, proprietary machine-learning algorithms, and at-home cheek swab collection kits for cancer identification. It offers mRNA-based screening to provide early insights of potential health risks. The company develops Revealia Breast test, a non-invasive cheek swab screening kit designed to identify and analyze molecular signatures in mRNA expression associated with inflammation-related biological processes associated with the presence of breast cancer. Ludwig Enterprises, Inc. was founded in 1988 and is based in Miami, Florida.
Selskapsinformasjon
33156 Miami, United States
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.